164 related articles for article (PubMed ID: 19414111)
21. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
Yu Y; Yu Q; Zhang X
Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
[TBL] [Abstract][Full Text] [Related]
22. Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.
Yu T; Tang B; Sun X
Yonsei Med J; 2017 May; 58(3):489-496. PubMed ID: 28332352
[TBL] [Abstract][Full Text] [Related]
23. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
24. Targeting the hypoxia-inducible factor (HIF) pathway in cancer.
Poon E; Harris AL; Ashcroft M
Expert Rev Mol Med; 2009 Aug; 11():e26. PubMed ID: 19709449
[TBL] [Abstract][Full Text] [Related]
25. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials.
Lam JS; Pantuck AJ; Belldegrun AS; Figlin RA
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):703s-708s. PubMed ID: 17255297
[TBL] [Abstract][Full Text] [Related]
26. Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma.
Siebenthall KT; Miller CP; Vierstra JD; Mathieu J; Tretiakova M; Reynolds A; Sandstrom R; Rynes E; Haugen E; Johnson A; Nelson J; Bates D; Diegel M; Dunn D; Frerker M; Buckley M; Kaul R; Zheng Y; Himmelfarb J; Ruohola-Baker H; Akilesh S
EBioMedicine; 2019 Mar; 41():427-442. PubMed ID: 30827930
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-inducible factors Per/ARNT/Sim domains: structure and function.
Scheuermann TH; Yang J; Zhang L; Gardner KH; Bruick RK
Methods Enzymol; 2007; 435():3-24. PubMed ID: 17998046
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-inducible factor 1 inhibitors.
Melillo G
Methods Enzymol; 2007; 435():385-402. PubMed ID: 17998065
[TBL] [Abstract][Full Text] [Related]
29. Novel therapeutics for metastatic renal cell carcinoma.
Hutson TE; Figlin RA
Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
[TBL] [Abstract][Full Text] [Related]
30. Current understanding of HIF in renal disease.
Rosenberger C; Rosen S; Heyman SN
Kidney Blood Press Res; 2005; 28(5-6):325-40. PubMed ID: 16534228
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability.
Eichelberg C; Junker K; Ljungberg B; Moch H
Eur Urol; 2009 Apr; 55(4):851-63. PubMed ID: 19155123
[TBL] [Abstract][Full Text] [Related]
32. Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer.
Srinivasan R; Linehan WM
J Clin Oncol; 2005 Jan; 23(3):410-2. PubMed ID: 15572728
[No Abstract] [Full Text] [Related]
33. Hypoxia-inducible factors--regulation, role and comparative aspects in tumourigenesis.
Hansen AE; Kristensen AT; Law I; Jørgensen JT; Engelholm SA
Vet Comp Oncol; 2011 Mar; 9(1):16-37. PubMed ID: 21303451
[TBL] [Abstract][Full Text] [Related]
34. Oxygen sensing: getting pumped by sterols.
Emerling BM; Chandel NS
Sci STKE; 2005 Jun; 2005(289):pe30. PubMed ID: 15972699
[TBL] [Abstract][Full Text] [Related]
35. New treatment approaches in renal cell carcinoma.
Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
[TBL] [Abstract][Full Text] [Related]
36. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
37. Short-term effects of pharmacologic HIF stabilization on vasoactive and cytotrophic factors in developing mouse brain.
Schneider C; Krischke G; Keller S; Walkinshaw G; Arend M; Rascher W; Gassmann M; Trollmann R
Brain Res; 2009 Jul; 1280():43-51. PubMed ID: 19450570
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-inducible factors and cancer.
Calzada MJ; del Peso L
Clin Transl Oncol; 2007 May; 9(5):278-89. PubMed ID: 17525038
[TBL] [Abstract][Full Text] [Related]
39. The role of hypoxia-inducible factor in osteogenesis and chondrogenesis.
Sun X; Wei Y
Cytotherapy; 2009; 11(3):261-7. PubMed ID: 19308769
[TBL] [Abstract][Full Text] [Related]
40. The intravenous anesthetics barbiturates inhibit hypoxia-inducible factor 1 activation.
Wakamatsu T; Tanaka T; Oda S; Nishi K; Harada H; Daijo H; Takabuchi S; Kai S; Fukuda K; Hirota K
Eur J Pharmacol; 2009 Sep; 617(1-3):17-22. PubMed ID: 19595685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
